Maegan Hoover

Maegan is a Principal Associate Scientist in the Discovery group at GentiBio. Maegan most recently came from Rubius Therapeutics, where she played an integral role in the preclinical development of several broadly stimulating anti-cancer cellular therapies. At Rubius, Maegan was fortunate to see two oncology candidates from initial proof of concept studies through to IND approval; one of which is currently in phase 1/2 clinical trials. Maegan began her industry career at Genocea Biosciences where she worked on T cell-focused vaccine development, assisting in mouse model development and early-stage immunogenicity and efficacy experiments for both the Chlamydia vaccine program and later a neoantigen-targeted personalized cancer vaccine program. Prior to industry work, Maegan spent several years in academia, working on a range of research topics, from the molecular drivers of RETT syndrome, long-term metabolic impacts of perinatal bisphenol A exposure, and pro-drug design for the treatment of cancer and type 1 diabetes. Maegan earned her B.A. in Biology from Connecticut College and received her Master of Science in the Biological Sciences, with a focus on molecular biotechnology, from Tufts University.